Open three-stage transthoracic oesophagectomy versus minimally invasive thoraco-laparoscopic oesophagectomy for oesophageal cancer: protocol for a multicentre prospective, open and parallel, randomised controlled trial

Juwei Mu, Shugeng Gao, Yousheng Mao, Qi Xue, Zuyang Yuan, Ning Li, Kai Su, Kun Yang, Fang Lv, Bin Qiu, Deruo Liu, Keneng Chen, Hui Li, Tiansheng Yan, Yongtao Han, Ming Du, Rongyu Xu, Zhaoke Wen, Wenxiang Wang, Mingxin Shi, Quan Xu, Shun Xu, Jie He, Juwei Mu, Shugeng Gao, Yousheng Mao, Qi Xue, Zuyang Yuan, Ning Li, Kai Su, Kun Yang, Fang Lv, Bin Qiu, Deruo Liu, Keneng Chen, Hui Li, Tiansheng Yan, Yongtao Han, Ming Du, Rongyu Xu, Zhaoke Wen, Wenxiang Wang, Mingxin Shi, Quan Xu, Shun Xu, Jie He

Abstract

Introduction: Oesophageal cancer is the eighth most common cause of cancer worldwide. In 2009 in China, the incidence and death rate of oesophageal cancer was 22.14 per 100 000 person-years and 16.77 per 100 000 person-years, respectively, the highest in the world. Minimally invasive oesophagectomy (MIO) was introduced into clinical practice with the aim of reducing the morbidity rate. The mechanisms of MIO may lie in minimising the reaction to surgical injury and inflammation. There are some randomised trials regarding minimally invasive versus open oesophagectomy, with 100-850 subjects enrolled. To date, no large randomised controlled trial comparing minimally invasive versus open oesophagectomy has been reported in China, where squamous cell carcinoma predominated over adenocarcinoma of the oesophagus.

Methods and analysis: This is a 3 year multicentre, prospective, randomised, open and parallel controlled trial, which aims to compare the effectiveness of minimally invasive thoraco-laparoscopic oesophagectomy to open three-stage transthoracic oesophagectomy for resectable oesophageal cancer. Group A patients receive MIO which involves thoracoscopic oesophagectomy and laparoscopic gastric mobilisation with cervical anastomosis. Group B patients receive the open three-stage transthoracic oesophagectomy which involves a right thoracotomy and laparotomy with cervical anastomosis. Primary endpoints include respiratory complications within 30 days after operation. The secondary endpoints include other postoperative complications, influences on pulmonary function, intraoperative data including blood loss, operative time, the number and location of lymph nodes dissected, and mortality in hospital, the length of hospital stay, total expenses in hospital, mortality within 30 days, survival rate after 2 years, postoperative pain, and health-related quality of life (HRQoL). Three hundred and twenty-four patients in each group will be needed and a total of 648 patients will finally be enrolled into the study.

Ethics and dissemination: The study protocol has been approved by the Institutional Ethics Committees of all participating institutions. The findings of this trial will be disseminated to patients and through peer-reviewed publications and international presentations.

Trial registration number: NCT02355249.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Flow chart of the study. ECOG PS, Eastern Cooperative Oncology Group Performance Status; MIE, minimally invasive oesophagectomy.

References

    1. Jemal A, Bray F, Center MM et al. . Global cancer statistics. CA Cancer J Clin 2011;61:69–90. 10.3322/caac.20107
    1. Chen W, Zheng R, Zhang S et al. . Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res 2013;25:10–21. 10.3978/j.issn.1000-9604.2012.12.04
    1. Connors RC, Reuben BC, Neumayer LA et al. . Comparing outcomes after transthoracic and transhiatal esophagectomy: a 5-year prospective cohort of 17 395 patients. J Am Coll Surg 2007;205:735–40. 10.1016/j.jamcollsurg.2007.07.001
    1. Wright CD, Kucharczuk JC, O'Brien SM, et al. , Society of Thoracic Surgeons General Thoracic Surgery Database. Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons general thoracic surgery database risk adjustment model. J Thorac Cardiovasc Surg 2009;137:587–96. 10.1016/j.jtcvs.2008.11.042
    1. Ping Y, He M, Meng X et al. . Prevention and treatment of complications after surgical resection for esophageal and gastric cardiac cancers. Zhonghua yixue zazhi 2009;89:296–300.
    1. Zhang DW, Cheng GY, Huang GJ et al. . Operable squamous esophageal cancer: current results from the east. World J Surg 1994;18:347–54. 10.1007/BF00316813
    1. Cuschieri A, Shimi S, Banting S. Endoscopic oesophagectomy through a right thoracoscopic approach. J R Coll Surg Edinb 1992;37:7–11.
    1. Maas KW, Biere SS, van Hoogstraten IM et al. . Immunological changes after minimally invasive or conventional esophageal resection for cancer: a randomized trial. World J Surg 2014;38:131–7. 10.1007/s00268-013-2233-0
    1. Luketich JD, Alvelo-Rivera M, Buenaventura PO et al. . Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 2003;238:486–94. 10.1097/01.sla.0000089858.40725.68
    1. Nafteux P, Moons J, Coosemans W et al. . Minimally invasive oesophagectomy: a valuable alternative to open oesophagectomy for the treatment of early oesophageal and gastro-oesophageal junction carcinoma. Eur J Cardiothorac Surg 2011;40:1455–63. 10.1016/j.ejcts.2011.01.086
    1. Sihag S, Wright CD, Wain JC et al. . Comparison of perioperative outcomes following open versus minimally invasive Ivor Lewis oesophagectomy at a single, high-volume centre. Eur J Cardiothorac Surg 2012;42:430–7. 10.1093/ejcts/ezs031
    1. Tsujimoto H, Takahata R, Nomura S et al. . Video-assisted thoracoscopic surgery for esophageal cancer attenuates postoperative systemic responses and pulmonary complications. Surgery 2012;151:667–3. 10.1016/j.surg.2011.12.006
    1. Mu J, Yuan Z, Zhang B et al. . Comparative study of minimally invasive versus open esophagectomy for esophageal cancer in a single cancer center. Chin Med J (Engl) 2014;127:747–52.
    1. Biere SS, van Berge Henegouwen MI, Maas KW et al. . Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012;379:1887–92. 10.1016/S0140-6736(12)60516-9
    1. Mariette V, Meunier B, Pezet D et al. . Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicenter, open-label, randomized phase III controlled trial, the MIRO trial. J Clin Oncol 2015;33(Suppl 3):5.
    1. van der Sluis PC, Ruurda JP, van der Horst S et al. . Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial). Trials 2012;13:230 10.1186/1745-6215-13-230
    1. Avery KN, Metcalfe C, Berrisford R et al. . The feasibility of a randomized controlled trial of esophagectomy for esophageal cancer—the ROMIO (Randomized Oesophagectomy: Minimally Invasive or Open) study: protocol for a randomized controlled trial. Trials 2014;15:200 10.1186/1745-6215-15-200
    1. Comparison of Ivor Lewis and Tri-incision Approaches for Patients with Esophageal Cancer. .
    1. Study of Neo-adjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Squamous Cell Esophageal Cancer (NACRFMIE). .
    1. Dunn DH, Johnson EM, Morphew JA et al. . Robot-assisted transhiatal esophagectomy: a 3-year single-center experience. Dis Esophagus 2013;26:159–66. 10.1111/j.1442-2050.2012.01325.x
    1. Puntambekar S, Kenawadekar R, Kumar S et al. . Robotic transthoracic esophagectomy. BMC Surg 2015;15:47 10.1186/s12893-015-0024-2
    1. Little AG, Lerut AE, Harpole DH et al. . The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction. Ann Thorac Surg 2014;98:1880–5. 10.1016/j.athoracsur.2014.07.069
    1. Allum WH, Bonavina L, Cassivi SD et al. . Surgical treatments for esophageal cancers. Ann N Y Acad Sci 2014;1325:242–68. 10.1111/nyas.12533
    1. Varghese TK Jr, Hofstetter WL, Rizk NP et al. . The Society of Thoracic Surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Ann Thorac Surg 2013;96:346–56. 10.1016/j.athoracsur.2013.02.069
    1. Seely AJ, Ivanovic J, Threader J et al. . Systematic classification of morbidity and mortality after thoracic surgery. Ann Thorac Surg 2010;90:936–42; discussion 942 10.1016/j.athoracsur.2010.05.014

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe